Waaler, Jo http://orcid.org/0000-0002-8501-6225
Mygland, Line
Tveita, Anders http://orcid.org/0000-0002-0668-9262
Strand, Martin Frank http://orcid.org/0000-0002-2588-5488
Solberg, Nina Therese
Olsen, Petter Angell
Aizenshtadt, Aleksandra
Fauskanger, Marte
Lund, Kaja
Brinch, Shoshy Alam
Lycke, Max
Dybing, Elisabeth
Nygaard, Vegard
Bøe, Sigurd Læines
Heintz, Karen-Marie
Hovig, Eivind http://orcid.org/0000-0002-9103-1077
Hammarström, Clara
Corthay, Alexandre http://orcid.org/0000-0001-9519-5725
Krauss, Stefan
Funding for this research was provided by:
Norges Forskningsråd (267639, 287990, 262814)
Ministry of Health and Care Services | Helse Sør-Øst RHF (16/00528-9, 15/00779-2, 2015012, 2019090)
Kreftforeningen (5803958, 189562, 181674, 197403)
Stiftelsen Kristian Gerhard Jebsen (SKGJ-MED-019)
Article History
Received: 1 December 2018
Accepted: 26 March 2020
First Online: 24 April 2020
Competing interests
: J.W. and S.K. hold patents related to tankyrase inhibitor therapy and these authors declare no additional interests. The remaining authors declare no competing interests.